Pseudomonas aeruginosa is an opportunistic Gram-negative bacterium that thrives in the damaged tissue of severe burns, where the loss of the skin barrier and prolonged hospitalization create ideal conditions for colonization. The organism is intrinsically resistant to many antimicrobial classes and readily acquires further resistance, and its capacity to form biofilms—structured bacterial communities encased in a self-produced extracellular matrix—makes eradication exceptionally difficult. Biofilms shield cells from antibiotics and immune defenses, driving therapeutic failure and recurrence in burn units and intensive care settings worldwide.

To gauge the scale of the problem in their region, the team collected 75 non-duplicate clinical P. aeruginosa isolates from patients at educational hospitals in Hamedan, Iran, between October 2024 and March 2025. Forty-nine isolates came from burn wounds and 26 from respiratory samples. Using Kirby-Bauer disk diffusion testing interpreted against Clinical and Laboratory Standards Institute breakpoints, the researchers found resistance was highest for ceftazidime at 78.67 percent, imipenem at 72 percent, and gentamicin at 69.33 percent. Overall, 57 isolates, or 76 percent, met the internationally accepted definition of multidrug resistance, meaning non-susceptibility to at least one agent in three or more antimicrobial categories.

Biofilm formation proved nearly universal. Seventy-four of the 75 isolates, or 98.7 percent, produced biofilms in the crystal violet microtiter assay, and every multidrug-resistant isolate did so, with 37 of the 57 classified as strong producers. From the burn-wound collection, the investigators selected nine isolates for detailed analysis—seven multidrug-resistant and two non-multidrug-resistant—all of which showed strong or intermediate biofilm formation, alongside the reference strain PAO1 as a standardized comparator.

The compound under investigation, (5-(3-methoxyphenyl)-1,3,4-oxadiazol-2-yl)(pyridin-2-yl)methanol, is a heterocyclic scaffold bearing a 3-methoxyphenyl substituent and a pyridin-2-yl methanol moiety, synthesized and characterized previously with purity above 95 percent confirmed by NMR. Against the nine selected burn isolates, the derivative yielded geometric mean minimum inhibitory and bactericidal concentrations of 20.54 and 41.21 micrograms per milliliter for planktonic cells. For biofilm-associated cells, the minimum biofilm inhibitory and eradication concentrations were 52.56 and 105.11 micrograms per milliliter, respectively. The higher eradication value reflects the well-known tolerance of mature biofilms, whose extracellular matrix limits drug penetration and access to embedded cells.

Checkerboard microdilution assays then tested whether the oxadiazole could potentiate gentamicin, an aminoglycoside protein synthesis inhibitor, and imipenem, a broad-spectrum carbapenem. Against planktonic cells, the gentamicin combination produced geometric mean fractional inhibitory and bactericidal concentration indices of 0.54 and 0.50, while the imipenem combination yielded 0.72 and 0.62. Against biofilm cells, the corresponding fractional biofilm indices ranged from 0.55 to 0.62, indicating similar gains in antibiofilm activity. Full synergy, defined as an index below 0.5, was observed in three of the nine isolates, with most others showing partial synergy, and no antagonism was detected in any combination.

The most mechanistically revealing results came from gene expression analysis. When the researchers exposed PAO1 and two clinical isolates to sub-inhibitory concentrations of the oxadiazole, quantitative real-time PCR revealed significant, concentration-dependent downregulation of two biofilm-associated genes: lasR, the master transcriptional regulator of the quorum-sensing system that coordinates virulence factor production and biofilm maturation, and algD, which encodes GDP-mannose dehydrogenase, the key enzyme in alginate biosynthesis that determines biofilm matrix thickness and stability. Log2 fold changes reached as low as minus 4.12 for both genes, with regression analysis showing strong concentration-response relationships and coefficients of determination between 0.888 and 0.969.

Because these transcriptional changes occurred at concentrations below the biofilm-inhibitory endpoint, the authors interpret them as evidence that the compound interferes with the regulatory machinery of biofilm formation rather than simply killing cells. They caution, however, that reduced gene expression alone does not establish a definitive molecular mechanism, since changes in viability or broader transcriptional responses could contribute, and that exopolysaccharide production and quorum-sensing signal levels were not directly measured in this study. Plausible mechanisms proposed for oxadiazoles elsewhere include disruption of bacterial membrane integrity, inhibition of essential enzymatic pathways, interference with nucleic acid synthesis, and altered permeability that enhances antibiotic uptake.

The dose-reduction implications are clinically significant. In previous work by the same group, the compound showed no significant cytotoxicity at concentrations up to 15.62 micrograms per milliliter, with an estimated IC50 range of 15.62 to 31.25 micrograms per milliliter. Combining the oxadiazole with gentamicin or imipenem lowered the fractional concentrations needed for antibacterial and antibiofilm effects, potentially allowing the compound to operate within its non-cytotoxic range while restoring activity to antibiotics against which the isolates had substantial resistance. The authors emphasize that the findings support the derivative as a promising adjunctive or alternative strategy for biofilm-related multidrug-resistant P. aeruginosa infections in burn patients, but that translation requires pharmacokinetic profiling, stable formulations, direct cytotoxicity testing of the combinations, and rigorous in vivo efficacy and toxicity studies in animal burn-infection models before clinical use can be considered.

Subject of Research: Antibacterial and antibiofilm activity of a 1,3,4-oxadiazole derivative against multidrug-resistant Pseudomonas aeruginosa from burn wound infections

Article Title: Antibacterial and antibiofilm properties of 1,3,4-oxadiazoles against multidrug-resistant Pseudomonas aeruginosa isolated from burn infections – an in vitro study

Article References: Nazari, M., Majzoobi, M. M., Alikhani, M. Y., & Imani Fooladi, A. A. (2026). Antibacterial and antibiofilm properties of 1,3,4-oxadiazoles against multidrug-resistant Pseudomonas aeruginosa isolated from burn infections – an in vitro study. International Microbiology. https://doi.org/10.1007/s10123-026-00890-5

Image Credits: AI Generated

DOI: 10.1007/s10123-026-00890-5

Keywords: Pseudomonas aeruginosa, burn wound infection, multidrug resistance, biofilm, 1,3,4-oxadiazole, lasR, algD, quorum sensing, synergistic therapy, gentamicin, imipenem, antimicrobial resistance